It made an important move to bolster its China business.
It's now the owner of a local distributor of its aesthetic products.
On a down Monday for the stock market, Bausch Health Companies (NYSE: BHC) shares rose at a double-digit rate. Investors, cheered by news of a fresh company acquisition, pushed its stock price up by more than 11% on the day.
Well before market open, Bausch announced that its Solta Medical aesthetics unit closed a deal to acquire China's Wuhan Shibo Zhenmei Technology. Wuhan is a distributor of Solta's products, so the arrangement effectively moves distribution in-house for the unit.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
In the press release trumpeting the acquisition of the new asset, Bausch did not provide any financial details of its purchase.
The healthcare company did write that "This acquisition provides Solta Medical with an enhanced ability to address increasing market demand for aesthetics treatments through localized solutions and proven technologies."
A popular Solta offering in the large Asian country is Thermage FLX, a non-invasive skin tightening solution.
Without concrete financial figures, investors are in the dark regarding what Bausch and its aesthetics business are sacrificing to own Wuhan. This, however, isn't as relevant as the company owning and fully controlling a distributor in one of the world's busiest markets. Investors were justified in reacting positively to Bausch's announcement of its latest deal.
Before you buy stock in Bausch Health Companies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bausch Health Companies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $580,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,084,986!*
Now, it’s worth noting Stock Advisor’s total average return is 1,004% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of December 1, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Bausch Health Companies. The Motley Fool has a disclosure policy.